BioSpace News Archive

The Lawrence J. Ellison Institute for Transformative Medicine of USC is pleased to announce the formation of a Policy Department and the hire of Gabriel Seidman, DrPH, as Director of Policy.

Biotech Veteran Brings Deep Scientific and Clinical Leadership to Immune-Onc as the Company Expands Clinical Development of its Novel Myeloid Checkpoint Inhibitors Recent $6M Award from the California Institute for Regenerative Medicine (CIRM) Will Further Accelerate Clinical Development of IO-202, a First-in-Class LILRB4 Antagonist Antibody

MustGrow’s safe and effective natural, organic biofumigant, biopesticide and bioherbicide are plant-based - harnessing the mustard seed’s natural defense mechanism to control diseases, insect pests and weeds.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of its 250 mg and 500 mg strength generic Erythromycin tablets—a therapeutic equivalent for the reference listed drug (RLD) Erythromycin Tablets from Arbor Pharmaceuticals.

Santen Canada Inc., a subsidiary of Santen Pharmaceutical Co., Ltd., a global company focused exclusively on ophthalmology, announced the approval of PRESERFLOTM MicroShunt by Health Canada.

NJ Biopharmaceuticals LLC, an expert provider of chemistry and biopharmaceutical services specializing in bioconjugation, custom synthesis, flow chemistry, and process development, announced the move of its headquarters from North Brunswick to Princeton, New Jersey.

A new case report, detailed in Annals of Emergency Medicine, is the first known case of a patient with VITT treated with a heparin alternative following the Centers for Disease Control and Prevention guidance.

Danaher Corporation announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Bank of America Healthcare Conference on Tuesday, May 11, 2021 at 2:00 p.m. ET.

Certara, Inc. (Nasdaq: CERT), the global leader in biosimulation, today announced the launch of its Secondary Intelligence™ software, the first and only software that quantitatively predicts the risk of adverse effects and safety issues derived from secondary pharmacology that may impede the clinical development of a drug.

Today CytoSMART Technologies has announced the release of its first fluorescence cell counter. The CytoSMART Exact FL is an automated, dual fluorescence cell counter with an expanded field of view and unmatched performance.